161 related articles for article (PubMed ID: 33938650)
1. Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.
Milićević S; Bergant D; Žagar T; Perić B
Croat Med J; 2021 Apr; 62(2):110-119. PubMed ID: 33938650
[TBL] [Abstract][Full Text] [Related]
2. Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.
Oczko-Wojciechowska M; Swierniak M; Krajewska J; Kowalska M; Kowal M; Stokowy T; Wojtas B; Rusinek D; Pawlaczek A; Czarniecka A; Szpak-Ulczok S; Gawlik T; Chmielik E; Tyszkiewicz T; Nikiel B; Lange D; Jarzab M; Wiench M; Jarzab B
Sci Rep; 2017 Feb; 7():42074. PubMed ID: 28181547
[TBL] [Abstract][Full Text] [Related]
3. Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.
Darabi S; Adeyelu T; Elliott A; Sukari A; Hodges K; Abdulla F; Zuazo CE; Wise-Draper T; Wang T; Demeure MJ
J Am Coll Surg; 2024 Jul; 239(1):50-60. PubMed ID: 38651727
[TBL] [Abstract][Full Text] [Related]
4.
Prabhash K; Saldanha E; Patil V; Bal M; Reddy P S; Sanjeev A; Kumar R; Poojary D; Noronha V; Menon N; Mittal N; Trivedi V; Nambiar K; Mishra R; Tanwar N; Malhotra R; Pange P; Gupta V; Veldore VH; Chougule A; Chaturvedi P; Dutt A; Chandrani P
JCO Precis Oncol; 2024 May; 8():e2300622. PubMed ID: 38754058
[TBL] [Abstract][Full Text] [Related]
5. RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.
Margraf RL; Mao R; Highsmith WE; Holtegaard LM; Wittwer CT
J Mol Diagn; 2007 Apr; 9(2):184-96. PubMed ID: 17384210
[TBL] [Abstract][Full Text] [Related]
6. Increased RET Activity Coupled with a Reduction in the
Okamoto M; Uesaka T; Ito K; Enomoto H
eNeuro; 2021; 8(3):. PubMed ID: 33958373
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathogenesis of pediatric thyroid carcinoma.
Mitsutake N; Saenko V
J Radiat Res; 2021 May; 62(Supplement_1):i71-i77. PubMed ID: 33978172
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
[TBL] [Abstract][Full Text] [Related]
9. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
Diquigiovanni C; Bonora E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
[TBL] [Abstract][Full Text] [Related]
10. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
[TBL] [Abstract][Full Text] [Related]
11. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
Passaro A; Attili I; Rappa A; Vacirca D; Ranghiero A; Fumagalli C; Guarize J; Spaggiari L; de Marinis F; Barberis M; Guerini-Rocco E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946519
[TBL] [Abstract][Full Text] [Related]
12. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
[TBL] [Abstract][Full Text] [Related]
13. Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Efstathiadou ZA; Tsentidis C; Bargiota A; Daraki V; Kotsa K; Ntali G; Papanastasiou L; Tigas S; Toulis K; Pazaitou-Panayiotou K; Alevizaki M
Eur Thyroid J; 2021 Apr; 10(2):125-139. PubMed ID: 33981617
[TBL] [Abstract][Full Text] [Related]
14. Spitz nevus with a novel TFG-NTRK2 fusion: The first case report of NTRK2-rearranged Spitz/Reed nevus.
Goto K; Pissaloux D; Tirode F; de la Fouchardière A
J Cutan Pathol; 2021 Sep; 48(9):1193-1196. PubMed ID: 33979462
[TBL] [Abstract][Full Text] [Related]
15. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
Han ZJ; Luo N; Li L; Liu ZL
Ann Palliat Med; 2021 Jul; 10(7):8413-8419. PubMed ID: 33977727
[TBL] [Abstract][Full Text] [Related]
16. Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma.
Raue F; Bruckner T; Frank-Raue K
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3582-e3591. PubMed ID: 33974051
[TBL] [Abstract][Full Text] [Related]
17. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
18. Editorial: 2021 European Society for Medical Oncology (ESMO) Recommendations on Laboratory Diagnostics for RET Gene Fusions and Mutations: A New Era in Targeted Therapy for RET-Altered Solid Tumors.
Parums DV
Med Sci Monit; 2021 May; 27():e933206. PubMed ID: 34024902
[TBL] [Abstract][Full Text] [Related]
19. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers.
Amar L; Pacak K; Steichen O; Akker SA; Aylwin SJB; Baudin E; Buffet A; Burnichon N; Clifton-Bligh RJ; Dahia PLM; Fassnacht M; Grossman AB; Herman P; Hicks RJ; Januszewicz A; Jimenez C; Kunst HPM; Lewis D; Mannelli M; Naruse M; Robledo M; Taïeb D; Taylor DR; Timmers HJLM; Treglia G; Tufton N; Young WF; Lenders JWM; Gimenez-Roqueplo AP; Lussey-Lepoutre C
Nat Rev Endocrinol; 2021 Jul; 17(7):435-444. PubMed ID: 34021277
[TBL] [Abstract][Full Text] [Related]
20. MANAGEMENT OF ENDOCRINE DISEASE: Papillary thyroid microcarcinoma: toward an active surveillance strategy.
Molinaro E; Campopiano MC; Elisei R
Eur J Endocrinol; 2021 Jun; 185(1):R23-R34. PubMed ID: 34010143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
